RSV Monoclonal Antibody Sales Surpass $19 Million

Sanofi today announced strong performance and increasing sales growth. In Q2 2024, Sanofi's sales were €10,745 million, up 10.2%.

In a press release on July 25, 2024, Paul Hudson, CEO, commented, “We are continuing our strong performance in 2024 and delivered broad-based, double-digit sales growth in the second quarter."

However, its very popular single-dose, extended half-life monoclonal antibody Beyfortus™ (Nirsevimab) offers passive immunization to prevent lower respiratory tract infections caused by the respiratory syncytial virus (RSV) to newborns and infants experiencing slow sales growth.

Beyfortus sales were limited to €18 million (USD $19.6), reflecting the global vaccine seasonality towards the second half-year. In the first quarter of 2024, Beyfortus produced €200 in sales.

In collaboration with AstraZeneca, responsible for Beyfortus manufacturing, the regulatory applications for two additional filling lines have been submitted to health authorities to expand supply for the Northern Hemisphere ahead of the 2024 - 2025 RSV season.

This production expansion is anticipated to augment capacity compared to the one licensed line.

According to media reports, access to Beyfortus is expected to meet demand in the United States during the second half of 2024.